Compare Stocks: IBIO, IPSC, ABEO, and SABS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.03 +0.4%	$6.00	$4.00 ▼ $7.65	$286.49M	1.31	1.42 million shs	1.21 million shs
IBIO iBio	$1.13 +1.4%	$1.33	$0.78 ▼ $3.82	$71.38M	1.26	497,827 shs	531,249 shs
IPSC Century Therapeutics	$1.53 -5.0%	$1.97	$0.44 ▼ $3.04	$291.53M	1.67	482,925 shs	802,950 shs
SABS SAB Biotherapeutics	$2.98 -2.6%	$3.59	$1.97 ▼ $5.15	$278.42M	0.58	601,721 shs	415,751 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-4.57%	-7.73%	-16.22%	-21.72%	-5.11%
IBIO iBio	-5.93%	-7.50%	-11.90%	-33.93%	+110,999,900.00%
IPSC Century Therapeutics	-5.57%	-4.73%	-20.69%	-33.74%	+222.13%
SABS SAB Biotherapeutics	-3.62%	-8.66%	-17.30%	-21.94%	+54.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.03 +0.4%	$6.00	$4.00 ▼ $7.65	$286.49M	1.31	1.42 million shs	1.21 million shs
IBIO iBio	$1.13 +1.4%	$1.33	$0.78 ▼ $3.82	$71.38M	1.26	497,827 shs	531,249 shs
IPSC Century Therapeutics	$1.53 -5.0%	$1.97	$0.44 ▼ $3.04	$291.53M	1.67	482,925 shs	802,950 shs
SABS SAB Biotherapeutics	$2.98 -2.6%	$3.59	$1.97 ▼ $5.15	$278.42M	0.58	601,721 shs	415,751 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-4.57%	-7.73%	-16.22%	-21.72%	-5.11%
IBIO iBio	-5.93%	-7.50%	-11.90%	-33.93%	+110,999,900.00%
IPSC Century Therapeutics	-5.57%	-4.73%	-20.69%	-33.74%	+222.13%
SABS SAB Biotherapeutics	-3.62%	-8.66%	-17.30%	-21.94%	+54.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	2.67	Moderate Buy	$21.00	317.50% Upside
IBIO iBio	3.11	Buy	$5.29	369.84% Upside
IPSC Century Therapeutics	2.43	Hold	$4.75	210.46% Upside
SABS SAB Biotherapeutics	2.73	Moderate Buy	$12.00	302.68% Upside

Current Analyst Ratings Breakdown

Latest IBIO, IPSC, ABEO, and SABS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/29/2026	IPSC Century Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/25/2026	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/25/2026	ABEO Abeona Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/21/2026	IBIO iBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/18/2026	ABEO Abeona Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$28.00 ➝ $30.00
9/17/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/17/2026	IBIO iBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
9/17/2026	ABEO Abeona Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$17.00
9/17/2026	ABEO Abeona Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$17.00
9/17/2026	IBIO iBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
9/3/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$5.82M	49.42	N/A	N/A	$2.94 per share	1.71
IBIO iBio	$100K	723.49	N/A	N/A	$1.54 per share	0.73
IPSC Century Therapeutics	$109.16M	2.54	$0.01 per share	121.05	$1.82 per share	0.84
SABS SAB Biotherapeutics	$1.32M	205.42	$0.33 per share	8.96	$3.18 per share	0.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	$71.18M	-$1.09	N/A	N/A	N/A	N/A	-41.69%	-30.36%	11/11/2026 (Estimated)
IBIO iBio	-$33.04M	-$0.34	N/A	N/A	N/A	N/A	-40.66%	-35.78%	11/11/2026 (Estimated)
IPSC Century Therapeutics	-$9.58M	-$0.93	N/A	N/A	N/A	N/A	-49.51%	-38.09%	11/12/2026 (Estimated)
SABS SAB Biotherapeutics	$13.27M	-$1.30	N/A	N/A	N/A	N/A	-6.74%	-6.06%	11/13/2026 (Estimated)

Latest IBIO, IPSC, ABEO, and SABS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/28/2026	Q4 2026	IBIO iBio	-$0.0655	-$0.04	+$0.0255	-$0.07	$0.08 million	N/A
8/13/2026	Q2 2026	ABEO Abeona Therapeutics	-$0.2317	-$0.35	-$0.1183	-$0.35	$12.24 million	$11.38 million
8/12/2026	Q2 2026	IPSC Century Therapeutics	-$0.11	-$0.17	-$0.06	-$0.17	$2.17 million	N/A
8/6/2026	Q2 2026	SABS SAB Biotherapeutics	-$0.2830	-$0.28	+$0.0030	-$0.28	$0.13 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.01	6.63	6.40
IBIO iBio	N/A	7.85	7.85
IPSC Century Therapeutics	N/A	8.28	8.28
SABS SAB Biotherapeutics	0.01	9.22	9.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
IBIO iBio	7.90%
IPSC Century Therapeutics	50.20%
SABS SAB Biotherapeutics	7.82%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	7.10%
IBIO iBio	1.55%
IPSC Century Therapeutics	2.40%
SABS SAB Biotherapeutics	7.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	226	57.18 million	53.12 million	Optionable
IBIO iBio	23	64.31 million	63.31 million	N/A
IPSC Century Therapeutics	78	181.07 million	176.73 million	Optionable
SABS SAB Biotherapeutics	86	90.99 million	84.26 million	Not Optionable

IBIO, IPSC, ABEO, and SABS Headlines

Recent News About These Companies

SAB Biotherapeutics, Inc. Announces Presentations Featuring SAB-142 Phase 1 Data At Breakthrough T1D Clinical & Research Congress

October 1 at 3:31 PM | marketscreener.comM

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

October 1 at 8:30 AM | globenewswire.com

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Has Average Price Target of $12.00 According to Analysts

September 30 at 2:44 AM | americanbankingnews.com

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Rated "Moderate Buy" by Sell-Side Analysts

September 30 at 2:43 AM | marketbeat.com

SAB Biotherapeutics (NASDAQ:SABS) Stock Price Down 2.4% - Here's What Happened

September 28, 2026 | marketbeat.com

SAB Biotherapeutics, Inc. Announces Presentations Of SAB-142 Data At The 62nd Annual Meeting Of The European Association For The Study Of Diabetes

September 22, 2026 | marketscreener.comM

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

September 22, 2026 | globenewswire.com

SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10, 2026 | seekingalpha.com

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of "Moderate Buy" by Brokerages

September 5, 2026 | marketbeat.com

SAB BIO to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and SAB Biotherapeutics (SABS)

August 8, 2026 | theglobeandmail.com

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

August 6, 2026 | globenewswire.com

SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment

July 15, 2026 | finance.yahoo.com

SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial

July 12, 2026 | theglobeandmail.com

SAB Biotherapeutics, Inc.: Breakthrough T1D Awards Grant to Support PRISE-hATG Study of SAB-142 in Stage 3 Type 1 Diabetes

July 7, 2026 | finanznachrichten.de

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

July 7, 2026 | globenewswire.com

Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?

July 6, 2026 | finance.yahoo.com

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

May 29, 2026 | finance.yahoo.com

SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

May 29, 2026 | globenewswire.com

Citigroup initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation

May 23, 2026 | msn.com

Why SAB Biotherapeutics, Inc.’s (SABS) Stock Is Up 7.01%

May 21, 2026 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, IPSC, ABEO, and SABS Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$5.03 +0.02 (+0.40%)

Closing price 04:00 PM Eastern

Extended Trading

$5.09 +0.06 (+1.19%)

As of 07:57 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

iBio NASDAQ:IBIO

$1.12 +0.02 (+1.35%)

Closing price 04:00 PM Eastern

Extended Trading

$1.10 -0.02 (-2.22%)

As of 07:55 PM Eastern

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Century Therapeutics NASDAQ:IPSC

$1.53 -0.08 (-4.97%)

Closing price 04:00 PM Eastern

Extended Trading

$1.62 +0.09 (+6.08%)

As of 07:55 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

SAB Biotherapeutics NASDAQ:SABS

$2.98 -0.08 (-2.61%)

Closing price 04:00 PM Eastern

Extended Trading

$3.06 +0.08 (+2.68%)

As of 07:30 PM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBIO, IPSC, ABEO, and SABS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBIO, IPSC, ABEO, and SABS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBIO, IPSC, ABEO, and SABS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, IPSC, ABEO, and SABS Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

iBio NASDAQ:IBIO

Century Therapeutics NASDAQ:IPSC

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBIO, IPSC, ABEO, and SABS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBIO, IPSC, ABEO, and SABS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBIO, IPSC, ABEO, and SABS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, IPSC, ABEO, and SABS Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

iBio NASDAQ:IBIO

Century Therapeutics NASDAQ:IPSC

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools